ClinicalTrials.gg
RecruitingNCT04088968STRONG-CSUpdated Mar 22, 2024

STRONG for Surgery & Strong for Life - Against All Odds: Intensive Prehabilitation for Risk Reduction in Cancer Surgery

An interventional study of Prehabilitation in Risk Reduction, Urological Cancer and Surgery, sponsored by Bispebjerg Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Bispebjerg Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Despite knowledge about the effect of preventive measures in lifestyle, smoking,nutrition, alcohol and physical activity (SNAP), there is a lack of systematic assessment of the overall lifestyle of the patient before surgery and knowledge about how lifestyle interventions can be organized in connection with cancer surgery. The intention with prehabilitation is to optimize the individual's risk factors and personal burdens that can affect the clinical and patient reported outcomes after surgery. The aim of this study is to evaluate the efficacy of intensive SNAP interventions compared to treatment as usual (TAU) in ptt undergoing urological cancer surgery on surgical risk reduction.

Read the detailed description

The project contains three clinical intervention studies, in total including 100 urological cancer patients screened positive for at least 1 SNAP factor:

I. Efficacy and preferences of intensive SNAP-Interventions among patients with at least one SNAP factor and undertaking neo-adjuvant chemotherapy before radical cystectomy. A randomised controlled trial with nested interviews (42 patients).

II. Implementation and preferences of intensive SNAP-Interventions among patients with kidney cancer undergoing nephrectomy/partial nephrectomy. An implementation feasibility study including interviews (20 patients).

III. Reach out and effect as well as preferences of perioperative intensive smoking cessation intervention via the municipality clinic compared to the surgical department among smokers with non-invasive bladder cancer treated with Trans-Urethral Resection of the Bladder (TUR-B). A randomised controlled trial with nested interviews (38 patients).

The intervention groups receive minimum five educational sessions tailored to individual needs over six weeks perioperatively. The control groups receive standard care.

02

Conditions studied

  • Risk Reduction
  • Urological Cancer
  • Surgery
  • Life Style

Keywords

  • Postoperative complications
  • Prehabilitation
  • Surgical risk reduction
  • Smoking
  • Alcohol drinking
  • Physical activity
  • Malnutrition
  • Obesity
  • Patient preferences
  • Randomised controlled trial
03

In context

Risk Reduction Behavior

291 studies on the registry are indexed under Risk Reduction Behavior; 38 are open to participants now.

This study's planned enrollment of 100 is below the median of 201 across 250 interventional studies indexed under Risk Reduction Behavior.

Browse Risk Reduction Behavior studies →

Lead sponsor

Bispebjerg Hospital is the lead sponsor of 289 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18 years scheduled for cystectomy due to bladder cancer
  • Referral to chemotherapy
  • Screened positive for minimum 1 SNAP factor
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and breastfeeding
  • Allergy to pharmaceutical support (Nicotine Replacement Therapy, Disulfiram)
  • to exercise.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Prehabilitation

    Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.

    Behavioral: Prehabilitation

  • No intervention
    Treatment as usual

    Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.

Interventions

  • BehavioralPrehabilitation

    Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.

    Also known as: smoking cessation, alcohol cessation, physical activity, nutritional support for malnutrition and obesity

06

What researchers measure

Primary outcomes

  1. Number of patients with risk reduction at surgery

    Corresponding at least 1 step for 1 or more risky lifestyles (but only smoking in study III) on the ASA-score (American Society of Anaesthesiologists physical status classification from 1-5, lower is better)

    Time frame: End of intervention/ at surgery

Secondary outcomes

  1. Health related quality of life (HRQoL)

    Mean difference of HRQoL between groups measured with EQ5D (5 level quality of life score (level 1 =no problems, level 2-5 =problems)

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  2. Number of patients with any postoperative complication

    Scored by the Comprehensive Complication Index, a linear scale ranging from 0 (no complication) to 100 (death)

    Time frame: 30 days

  3. Number of successful tobacco quitters

    Successful quitting smoking: Study I+ II+ III * Successful quitting alcohol intake at 6 weeks and below risky limits at 6 months: Study I. * Physical activity at least 30 minutes per day: Study I. * Malnutrition: Not at risk of malnutrition: Study I. Obesity: 5% -10 % loss of body fat mass and below 1% gain of body fat mass at 6 months (without developing malnutrition)

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  4. Number of successful alcohol quitters

    Successful quitting alcohol: Study I+II

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  5. Number of patients being physical active at least 30 min per day

    Minutes physical active measured by an accelerometer (longer time is better) : Study I+II

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  6. Number of patients not at risk of malnutrition

    NRS2002 (Nutritional Risk Screening 2002) score\>2. Lower is better: Study I+II

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  7. Number of patients not at risk of obesity

    BMI (Body Mass Index)\<30. Lower is better : Study I+II

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  8. Number of patients with improved frailty level

    Measured by Lammers definition: Lower is better: Study I+II+III

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

  9. Number of patients with any reduction in lifestyle

    Measured by yes/no. Study I+II+III

    Time frame: 6 weeks/day at surgery, at 1 month and through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
  • Dept Urology 2112, Copenhagen University Hospital, Rigshospitalet
    Copenhagen, Region H 2100, Denmark
    Recruiting
08

References and documents

Publications

  • Tonnesen H, Lydom LN, Joensen UN, Egerod I, Pappot H, Lauridsen SV. STRONG for Surgery & Strong for Life - against all odds: intensive prehabilitation including smoking, nutrition, alcohol and physical activity for risk reduction in cancer surgery - a protocol for an RCT with nested interview study (STRONG-Cancer). Trials. 2022 Apr 21;23(1):333. doi: 10.1186/s13063-022-06272-2. PubMed 35449008 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2025, 41 months after the start.

Of 167 non-industry interventional studies with no phase under Risk Reduction Behavior, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 41 months is above that.

Counting every sponsor, half of 169 studies reached it within 25 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Sep 13, 2019
StartActual
Jan 1, 2022
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04088968
Responsible party
Hanne Tonnesen (Professor, Bispebjerg Hospital) — Principal investigator
First posted
Sep 13, 2019
Start date
Jan 1, 2022
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 22, 2024

Study contacts

Hanne Tønnesen, Professor MD
Contact
hanne.tonnesen@regionh.dk
+4538163840
Susanne V Lauridsen, PhD
Contact
susanne.vahr.lauridsen@regionh.dk
+4535451704
Hanne Tonnesen, Professor MD
principal investigator · WHOCC, The Parker Institute, Bispebjerg-Frederiksberg Hospital, RegH, Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion